Unless otherwise stated, all compounds and solvents were used as received. 4-hydroxyazobenzene, 2’-dihydroxyazobenzene, and AIBN were acquired from Aldrich. AIBN was recrystallized in methanol prior to use. HEMA, MMA, and PMMA (≈35 k) were acquired from Acros Organics.
TEGDMA,
2-hydroxybenzyl alcohol, and
acyl chloride were acquired from Tokyo Chemical Industry.
N,
N-dimethylformamide (DMF), triethylamine, and
silica gel were acquired from Fisher. THF was acquired from VWR. Dichloromethane (DCM) was acquired from Millipore.
Rhodamine B was acquired from PolySciences.
S. mutans American Type Culture Collection (ATCC 25175),
S. aureus (Herbert, 2010 HG001 or AH2183 or RN1HG),
S. oralis (ATCC 9811), and
A. actinomycetemcomitans (ATCC 43718), and
E. coli (Mysorekar, 2013) were provided from the sources listed. BBL BHI media and
Difco agar were acquired from Becton, Dickinson and Company.
Sucrose for cell growth was acquired from MP Biomedicals, LLC. Phosphate-buffered saline (PBS) was acquired from Bioland Scientific. Dulbecco’s modified eagle medium (DMEM) media and
fetal bovine serum (FBS) was acquired from Fisher.
Penicillin-streptomycin and trypsin solution 10X (2.5%) was acquired from Aldrich.
Mori D.I., Schurr M.J, & Nair D.P. (2020). Selective Inhibition of Streptococci Biofilm Growth via a Hydroxylated Azobenzene Coating. Advanced materials interfaces, 7(15), 1902149.